Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee's glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide. The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. Under the agreement, Gan & Lee is eligible to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!